Clinical Trial Results: Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating the safety and bioactivity of the ipilimumab and nivolumab combination in patients with hepatocellular carcinoma prior to liver resec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Imperial College London | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-06-29